Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry
Ημερομηνία
2016Γλώσσα
en
Λέξη-κλειδί
Επιτομή
Osteomyelitis is a serious infection predominantly caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Orthopaedic device-related infections are complex and require a careful combination of surgical intervention and antimicrobial therapy. Daptomycin, a cyclic lipopeptide, effectively penetrates soft tissue and bone and demonstrates rapid concentration-dependent bactericidal activity against Gram-positive pathogens. This retrospective, non-interventional study evaluated clinical outcomes in patients with osteomyelitis or orthopaedic device infections treated with daptomycin from the European Cubicin® Outcomes Registry and Experience (EU-CORESM) study. Patients were treated between January 2006 and April 2012, with follow-up to 2014. Clinical outcomes were assessed as success (cured or improved), failure or non-evaluable. Of 6,075 patients enrolled, 638 (median age, 63.5 years) had primary infections of osteomyelitis or orthopaedic device infections, 224 had non-prosthetic osteomyelitis, 208 had osteomyelitis related to a permanent or temporary prosthetic device, and 206 had orthopaedic device infections. The most commonly isolated pathogen was S. aureus (214 [49.1 %]; 24.8 % were MRSA). Overall, 455 (71.3 %) patients had received previous antibiotic therapy. Patients underwent surgical interventions, including tissue (225 [35.3 %]) and bone (196 [30.7 %]) debridement, as part of their treatment. Clinical success rates were 82.7 % and 81.7 % in S. aureus and coagulase-negative staphylococcal infections. Adverse events (AEs) and serious AEs assessed as possibly related to daptomycin were observed in 6.7 % and 1.9 % of patients, respectively. Daptomycin was discontinued by 5.5 % of patients due to AEs and 10 (1.6 %) deaths were reported. In conclusion, daptomycin was effective and safe in patients with osteomyelitis or orthopaedic device infections. © 2015, The Author(s).
Collections
Related items
Showing items related by title, author, creator and subject.
-
Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis
Thomas K., Lazarini A., Kaltsonoudis E., Voulgari P.V., Drosos A.A., Repa A., Sali A.M.I., Sidiropoulos P., Tsatsani P., Gazi S., Evangelia A., Boki K.A., Katsimbri P., Boumpas D., Fragkiadaki K., Tektonidou M.G., Sfikakis P.P., Karagianni K., Sakkas L.I., Grika E.P., Vlachoyiannopoulos P.G., Evangelatos G., Iliopoulos A., Dimitroulas T., Garyfallos A., Melissaropoulos K., Georgiou P., Areti M., Georganas C., Vounotrypidis P., Georgiopoulos G., Kitas G.D., Vassilopoulos D. (2021)Objectives: Predicting serious infections (SI) in patients with rheumatoid arthritis (RA) is crucial for the implementation of appropriate preventive measures. Here we aimed to identify risk factors for SI and to validate ... -
Daptomycin Use in Children: Experience with Various Types of Infection and Age Groups
Syrogiannopoulos G.A., Michoula A.N., Petinaki E., Grivea I.N. (2017)Background: In Greece, there are high rates of methicillin (40%-60%) and clindamycin (15%-25%) resistance among community-acquired Staphylococcus aureus isolates. Therefore, we sought to identify other antimicrobial treatment ... -
Peritoneal dialysis-related infections recommendations: 2016 update. What is new?
Liakopoulos V., Nikitidou O., Kalathas T., Roumeliotis S., Salmas M., Eleftheriadis T. (2017)In 2016, the International Society of Peritoneal Dialysis (ISPD) published guidelines that focus on the importance of both prevention and treatment of peritonitis. For once more, the need for annual reporting of peritonitis ...